Drug Profile
Research programme: factor Xa inhibitors - Schering-Plough
Alternative Names: Factor Xa inhibitors research programme - Schering-Plough; Oral anticoagulants research programme - Schering-PloughLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Dendreon San Diego LLC
- Developer Schering-Plough
- Class
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Deep vein thrombosis; Embolism; Myocardial infarction; Unstable angina pectoris
Most Recent Events
- 26 Sep 2002 Corvas International has terminated its involvement in the research collaboration
- 03 Feb 1999 Preclinical development for Deep vein thrombosis in USA (PO)
- 03 Feb 1999 Preclinical development for Embolism in USA (PO)